Please log in
to access more information

loading...

User name and Password not recognised

Home Page > The Company > Board of Directors

Board of Directors

Jan Ohrstrom Jan Ohrstrom, MD
Chairman

Dr. Ohrstrom is a Senior Executive with international experience in Biotechnology and Pharma. He has held Management positions in Large and Mid-Cap US/EU Biopharma companies, amongst them Novo Nordisk, ZymoGenetics, ProFibrix and The Medicines Company. Dr. Ohrstrom was part of the Management Team that took ZymoGenetics public on Nasdaq, where he also spearheaded the development and approval of Recothrom. Dr. Ohrstrom incorporated ProFibrix Inc in 2008 and in 2013 as CEO led the company through an M&A with The Medicines Company. ProFibrix’s lead compound Raplixa was approved in 2015 in the US and EU. Dr. Ohrstrom is a Board member of Blaze Bioscience in Seattle and has held other board positions in private and public life science companies.

Marie-Claire Janailhac-Fritsch Marie-Claire Janailhac-Fritsch
Independent Director

A graduate of the Business School HEC Paris (Ecole des Hautes Etudes Commerciales de Paris), Marie-Claire Janailhac Fritsch occupied a number of functions in different pharmaceutical companies over a period of 10 years, and for 17 years she participated in the creation, development and sale of startups in the cosmetic sector. Since 2003, Marie-Claire Janailhac Fritsch has worked as a consultant in the cosmetics sector. On September 30, 2013 she was appointed chair of the board of directors of Guerbet, the French pharmaceutical group specializing in medical imaging. Marie-Claire Janailhac-Fritsch has been a member of the French Institute of Directors (Institut Français des Administrateurs) since 2007.

Abbas Ardehali, MD, FACS Abbas Ardehali, MD, FACS
Independent Director

Dr. Abbas Ardehali is a practicing Cardiothoracic Surgeon in Los Angeles, California. Dr. Ardehali graduated from Emory University School of Medicine in 1986 and has been in practice for 31 years. He also specializes in Cardiology (Cardiovascular Disease) and Vascular Surgery, and currently practices at Ronald Reagan UCLA Medical Center and is affiliated with Ronald Reagan UCLA Medical Center and West Los Angeles Medical Center. Dr. Ardehali is a polyglot who, in addition to English, has language proficiency in Vietnamese, Russian, Spanish, Polish, Arabic, French, Korea and Italian.

Erin Gainer Erin Gainer
Independent Director

Erin Gainer holds a bachelor’s degree in biology and in English from Rice University and a master’s degree in public health from The Johns Hopkins University. She earned her Ph.D. in epidemiology from the University of Paris XI and completed her MBA for Executives at INSEAD. From 2000 to 2009, she was executive director of research and development at HRA Pharma. There she was HRA Pharma’s chief executive officer from 2009-2016 and since 2016 has been chair of the board of directors. Erin Gainer created the foundation ELLA in 2016 devoted to promoting the empowerment of women throughout the world through education, health and entrepreneurship.

Peter Byloos Peter Byloos, MD
Independent Director

Dr. Byloos possesses extensive experience in the healthcare sector. Currently CEO of Optegra Eye Health Care, a UK based eye treatment company, he previously served as CEO and President of Handicare, the specialized Norwegian equipment provider for the elderly and disabled and has occupied several International Leadership positions with CR Bard, a US medical device company, where he gained widespread knowledge of the surgical hemostasis market. Dr. Byloos, also worked for Gimv, the European investment firm and one of Biom’up’s historical shareholders, where he was a Partner and responsible for the development of the Health & Care platform. He is a Medical Doctor from the University of Leuven (Belgium) and holds a Master of Science in Management from the Boston University (USA).

Karl Nägler Karl Nägler
Director

Karl joined Gimv in 2011 as Partner. Having started his professional career in 2002 at Atlas Venture in London and Munich, he later joined Ventech, a Paris-based venture capital firm focused on Europe and China.
Karl has a successful track record in early and later stage Life Science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe, including U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (acquired by Horizon Pharma, HZNP:US), Egalet (EGLT:US), Funxional Therapeutics (acquired by Boehringer Ingelheim) and Themis.
Since he joined Gimv, Karl has led investments into Prosonix (acquired by Circassia, CIR:LN), Covagen (acquired by Johnson & Johnson, JNJ:US) and Biom'up and has represented Gimv on the boards of those companies as well as on the board of Actogenix (acquired by Intrexon, XON:US).
Previously, Karl had worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg (France) and holds a PhD in the area of molecular neurobiology from the Max-Delbrück-Center for Molecular Medicine (Berlin) and a Diploma in Biology from the Free University of Berlin.